182 related articles for article (PubMed ID: 24808637)
21. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
22. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M
J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653
[TBL] [Abstract][Full Text] [Related]
23. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
24. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
25. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.
Isaacs JT
J Steroid Biochem; 1983 Jun; 18(6):749-57. PubMed ID: 6191128
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2.
Hong GL; Park SR; Jung DY; Karunasagara S; Lee KP; Koh EJ; Cho K; Park SS; Jung JY
J Ethnopharmacol; 2020 Mar; 250():112446. PubMed ID: 31812646
[TBL] [Abstract][Full Text] [Related]
27. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate.
Geller J; Albert J; Lopez D; Geller S; Niwayama G
J Clin Endocrinol Metab; 1976 Sep; 43(3):686-8. PubMed ID: 60347
[TBL] [Abstract][Full Text] [Related]
28. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
Pejčić T; Tosti T; Tešić Ž; Milković B; Dragičević D; Kozomara M; Čekerevac M; Džamić Z
Prostate; 2017 Jul; 77(10):1082-1092. PubMed ID: 28594074
[TBL] [Abstract][Full Text] [Related]
29. Finasteride accelerates prostate wound healing after thulium laser resection through DHT and AR signalling.
Zhao R; Wang X; Jiang C; Shi F; Zhu Y; Yang B; Zhuo J; Jing Y; Luo G; Xia S; Han B
Cell Prolif; 2018 Jun; 51(3):e12415. PubMed ID: 29194865
[TBL] [Abstract][Full Text] [Related]
30. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
[TBL] [Abstract][Full Text] [Related]
31. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
32. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis.
Jin BR; An HJ
Aging (Albany NY); 2020 Feb; 12(3):2142-2155. PubMed ID: 32018227
[TBL] [Abstract][Full Text] [Related]
33. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
[TBL] [Abstract][Full Text] [Related]
34. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.
Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK
Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360
[TBL] [Abstract][Full Text] [Related]
35. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
36. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat.
di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485
[TBL] [Abstract][Full Text] [Related]
37. Lovastatin-induced apoptosis in prostate stromal cells.
Padayatty SJ; Marcelli M; Shao TC; Cunningham GR
J Clin Endocrinol Metab; 1997 May; 82(5):1434-9. PubMed ID: 9141529
[TBL] [Abstract][Full Text] [Related]
38. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
39. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
40. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
